Monday, 31 October 2011

MONOSAN Xtra Detection Systems

The Monosan® Polymer Detection Systems utilize a novel controlled polymerization technology to prepare polymeric HRP-linker antibody conjugates. Therefore, the problem of non-specific staining that can occur with Streptavidin/Biotin detection systems due to endogenous biotin does not occur.

These products are used in an immunohistochemical (IHC) procedure, which allows the qualitative identification by light microscopy of antigens in sections of formalin-fixed, paraffin-embedded tissue, via sequential steps with interposed washing steps. If required by the primary antibody, sections are subjected to epitope retrieval prior to staining. Endogenous peroxidase activity is neutralized using the Peroxidase Block (Product Code: MON-APP145).

This is followed by application of Protein Block to reduce non-specific binding of primary and polymer. The section is subsequently incubated with optimally diluted primary antibody. Monosan® Post Primary Block is used to enhance penetration of the subsequent polymer reagent. The Monosan® Polymer recognizes mouse and rabbit immunoglobulins, it detects any tissue-bound primary antibody. Sections are further incubated with the substrate/chromogen, 3,3’ - diaminobenzidine (DAB), prepared from Monosan® DAB Chromogen and Monosan® DAB Substrate Buffer (Polymer), as described below. Reaction with the peroxidase produces a visible brown precipitate at the antigen site. Sections are counterstained with Hematoxylin and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.

For more product information click here.

Friday, 28 October 2011

NCRI Cancer Conference

On 6th-8th November 2011 we will be in Liverpool exhibiting at the National Cancer Research Institute Cancer Conference.

NCRI held its first national cancer conference, covering all aspects of cancer research, in 2005 and has since become an annual event. It aims to encourage the sharing of knowledge, ideas and best practice, and to promote cross-disciplinary collaboration.

The National Cancer Research Institute (NCRI) is a UK-wide partnership between the government, charity and industry which promotes co-operation in cancer research among the 22 member organisations for the benefit of patients, the public and the scientific community.

The NCRI Cancer Conference is the major forum in the UK for showcasing the best British and international cancer research being held at The BT Convention Centre in Liverpool, from 6-9 November. As in previous years, the Conference brings together the leading experts across all disciplines and will involve a mix of high quality plenary speakers, symposia, and parallel sessions, together with poster sessions and industry-sponsored commercial workshops, over a period of four days.

For more information on this conference visit the website.
To view the programme click here.

Prof. Nic Jones, Chief Scientist of Cancer Research UK and Director of the Manchester Cancer Research Centre, discusses the highlights of the 2011 NCRI Cancer Conference programme. As Chair of the 2011 Conference Programme Committee, he presents an exciting insight on the Conference and why professionals involved in all areas of oncology should attend.

Thursday, 27 October 2011

DLL1 & DLK1 - Key Ligands of the Notch Signalling Pathway


The Notch signalling pathway is essential for cell differentiation and cell fate decisions. The components have been associated with various disorders such as cancer, leukaemia, immune disorders, developmental syndromes, stroke, cognitive symptoms and metabolic disorders.

Delta-like Protein 1 (DLL1) is essential for postnatal arteriogenesis and contributes to tumour progression. DLL1 is involved in differentiation and self-renewal of adipocyte stem cells. Thus the measurement of soluble DLL1 in serum or plasma is like to provide a novel indication of disease status in metabolic dysfunctions.

Protein Delta homolog 1 (DLK1) is a regulator of adipocyte differentiation found in serum and urine. Levels of soluble DLK1 affect negatively or positively adipogenesis and control mesenchymal cell fate. ALK1 is frequently up regulated in myelodysplastic syndrome (MDS) patients compared to non- leukemic individuals.



DLL1 Soluble ELISA Kit (human) - Potential Biomarker for Metabolic Disorders


DLK1 Soluble ELISA Kit (human) - Potential Biomarker for
Metabolic Disorders
Product Code: AG-45A-0032

Tuesday, 25 October 2011

Special Offer on Multi-Kinase ELISA Array Kits from Symansis


Discounts Off Symansis Multi-Kinase ELISA Array Kits.


The Symansis’ MKA ELISA kits provide an easier and faster alternative than traditional western blots (NEW 2.5 hour protocol), have a significantly greater dynamic range and sensitivity than western blots, can operate with much less sample (5-20 micrograms total protein), and are more cost-effective than westerns with up to six data points per assay if desired. The kits are designed to demonstrate the qualitative differences in the amounts of specific target proteins between samples.

For more information regarding this offer click here or please email office@caltagmedsystems.co.uk.

Friday, 21 October 2011

ECP/EDN ELISA: Eosinophil and bronchial asthma


The pathology of bronchial asthma suggests bronchial inflammation is mainly caused by leukocytes and eosinophils.
Eosinophils and leukocytes are recognized as permeating tunica mucosa bronchiorum in patients with chronic bronchial asthma in both atopic and non-atopic conditions. When stimulated, the respiratory epithelial cells induce production and release various cytokines. Cytokines such as granulocyte-macrophage colony stimulating factors (GM-CSF) retain biological activities for eosinophils; their activities can include maturity, differentiation, migration and life prolongation. Activated eosinophils secrete granular proteins that injure and exfoliate the respiratory epithelium. They also release active oxygen with the ability of injuring cells, which can constrict bronchial smooth muscle and platelet-activating factors attractive for eosinophils and neutrophils. As a result, these substances cause bronchoconstriction, hyper transmission of blood vessels and hypersecretion of mucus.

Eosinophil Cationic Protein (ECP), Eosinophil Derived Neurotoxin (EDN) and Major Basic Protein (MBP) are known to be major protein-mediators derived from activated eosinophils. Activated eosinophils play an important role in inflammatory processes especially in allergic diseases. The levels of eosinophil activation can serve as complementary data for monitoring asthma inflammation. As ECP/EDN proteins are secreted from activated eosinophils they can become markers of eosinophil activation and degranulation which can cause inflammatory disease of the airway.


  • No cross reactivity with EDN
  • For use with human serum samples
  • No cross reactivity with ECP
  • For use with human serum samples

Thursday, 20 October 2011

The Paterson Institute for Cancer Research Vendor Day


On 26th October 2011 we will be in Manchester at the Paterson Institute for Cancer Research, why not come along and visit us.

The Paterson Institute for Cancer Research is a leading cancer research institute within the University of Manchester, core funded by Cancer Research UK, the largest independent cancer research organisation in the world. Research spans the whole spectrum of cancer research, from programmes investigating molecular and cellular basis of cancer, to those focussed on translational research and development of therapeutics.

The Institute supports a number of investigative programmes, spanning both basic and translational cancer research. It has excellent laboratory facilities and outstanding core services, including microarrays, confocal microscopy, bioinformatics, histology, and access to mass-spectrometry based proteomics.

The Institute works in close collaboration with The Christie Hospital and is a partner in the newly formed Manchester Cancer Research Centre. Their aim is to gain a greater understanding of the fundamental basis of how cancer develops and apply that knowledge to develop new diagnostic tests, potential treatments and better ways to predict the outcomes.


We will be located in the coffee room, from 10am – 4pm, so don’t be shy, come and see us for your chance to win a spooky Halloween treat!

For more information on this vendor day email: enquiries@picr.man.ac.uk or office@caltagmedsystems.co.uk

Wednesday, 19 October 2011

ELRIG - Stem Cells and Regenerative Medicine



Visit us at stand 21 on 8th November in Hinxton Hall, Cambridge. This conference, Stem Cells and Regenerative Medicine, will highlight state of the art research and technology enabling the provision of stem cells, their differentiation into desired cell types as well as applications as potential therapeutic agents.

The provision of Stem Cells and their derived progeny is one of the most promising high impact developments in modern medical science. In pharmaceutical research they have been harnessed to provide a plethora of highly characterised cells for a wide range of applications. More direct applications of stem cells are also enabling the development of a whole new field of therapy, Regenerative Medicine, focusing on the underlying causes of diseases by effectively replacing or regenerating the damaged cells themselves.

Registration for this event is FREE. Follow this link to register your details.

Speaker programme includes:
“Stem cells and the applications to regenerative medicine and drug testing” – Malcolm Alison, QMUL
“Optimising the production of Red Blood Cells from haematopoietic stem cells” – Katie Glen, Loughborough University
“Human embryonic stem cells derived hepatocytes and bioartificial liver development” – Sebastian Greenhough, Edinburgh University
“Towards regeneration of the ocular surface” – Julie Daniels, UCL

To view the full speaker programme and for more information about this event, please go to the ELRIG website.

Tuesday, 18 October 2011

Diabetes, Obesity and Metabolism ELISA's from Symansis


Symansis have a new range of ELISA kits for research within the areas of diabetes, obesity and metabolism. These include insulin, fatty acid binding protein and FGF-21 ELISA arrays.



Fatty Acid Binding Protein 4/aP2 Human ELISA Array
Product code: EFABP4SY

Fatty-acid binding protein 4 (FABP4), also termed adipocyte fatty-acid binding protein (A-FABP), or aP2, is a novel adipocyte-expressed factor which accounted for ~6% of total cellular proteins. Several animal experiments suggested that FABP-4 plays a key role in the link between obesity and various features of metabolic syndrome. Mice with targeted disruption of FABP-4 accompany FABP-5 almost completely protect against diet-induced obesity, insulin resistance, dyslipidemia, type 2 diabetes, and fatty liver disease. Studies in humans found FABP-4 serum levels were significantly increased in overweight and obese subjects, which predicted the risk to develop a metabolic syndrome and type 2 diabetes. Additionally, serum FABP-4 levels were associated with nonalcoholic fatty liver disease, carotid atherosclerosis and coronary artery disease.


FGF-21 ELISA Arrays

Fibroblast growth factor 21 (FGF-21) is a novel protein that has been implicated in the regulation of lipid and glucose metabolism under fasting and ketotic conditions. In murine models, FGF-21 is predominantly expressed in liver, but it also expressed in adipose tissue and pancreatic ß-cells. FGF-21 stimulates glucose uptake in adipocytes. It also protects animals from diet-induced obesity when overexpressed in transgenic mice and lowers blood glucose and triglyceride levels when administered to diabetic rodents. Furthermore, elevated plasma FGF-21 concentrations in humans appear to be related to the presence of hepatic and peripheral insulin resistance.

Download the datasheet here – Human & Mouse/Rat

Insulin ELISA Arrays

Ultra Sensitive Insulin Kits
Product code: EUSRISY (rat)
Product code: EUSMISY (mouse)

These kits are designed for the quantitative determination of insulin in rat/mouse serum and plasma in lean/healthy rats and mice as the level of insulin is extremely low. The ultra-sensitive kit is too sensitive to be used for obese/hit fat rat model systems.


High Sensitive Insulin Kits
Product code: EHSRISY (rat)
Product code: EHSMISY (mouse)

Kits are designed for the quantitative determination of insulin in rat/mouse serum and plasma from high fat diet-induced obese rat/mouse model systems.


Wide Range Insulin Kits
Product code: EWRRISY (rat)
Product code: EWRMISY (mouse)

For the quantitative determination of insulin in rat or mouse serum, plasma and fluid over a wide range from 1 ng/ml to 50 ng/ml. These kits are excellent for drug screening experiments or initial screening experiments where insulin levels are not known.

Download the datasheet here – Rat & Mouse

Monday, 17 October 2011

R-Phycoerythrin (R-PE) - (phycobiliprotein of red algae)


Phycoerythrin (R-PE) is a constituent part of the photosynthesis apparatus of red algae. It consists of a protein and 34 phycoerythrobilin fluorochromes. This fluorochrome/protein ratio is the main reason for the bright intensity of R-PE. However, the low degree of photostability limits its range of application. Its high molecular weight and tendency to agglomerate must be taken into consideration during the use of R-PE conjugates. Non-specific binding of the fluorochrome to cells is occasionally observed. R-PE-conjugated antibodies should not be stored at -20°C, as freezing damages the fluorochrome.

Flow Cytometry

R-PE can be measured on all standard commercial flow cytometers and sorters. Its high light intensity makes it the fluorochrome of choice in the detection of antigens expressed in low concentrations. The R-PE fluorochrome is also often used in multicolour analysis. However, the spectral characteristics of R-PE require compensation with FITC and fluorochromes in the long-wave emission range. For intracellular stainings the size of the fluorochrome should be weighed against its bright intensity. Under certain circumstances it may be advantageous to use Alexa Fluor® conjugates, or FITC conjugates for intracellular applications.

To view Caltag Laboratories range of R-PE fluorochromes click here.

To view the full range of Caltag Laboratories fluorochromes and their applications click here.

Friday, 14 October 2011

Autophagy Research


Autophagy was first discovered in yeast as a starvation response, in which cells digest portions of their cytoplasm to generate nutrients. In mammalian cells, autophagy has been shown to have additional functions and has been implicated in neuronal degradation, infectious disease, heart disease and cancer. MBL provides antibodies at a concentration of 1mg/ml and extensively validated for applications such as immunocytochemistry (ICC), immunohistochemistry (IHC), western blotting (WB), immunoprecipitation (IPP) and flow cytometry (FCM).

The most studied autophagy target is Atg8 which is present throughout the entire autophagy process. There are three mammalian homologues of yeast Atg8: LC3 (MICROTUBULE-ASSOCIATED PROTEIN 1, LIGHT CHAIN 3, ALPHA), GABARAP (GABAA receptor associate protein) and Gate-16 (Golgi –associated ATPase enhancer). Among these LC3 is the best characterized and is most commonly used as a autophagosome marker.

Yeast Atg14 has also long been known to be essential for autophagy, but its mammalian homologue Atg14L only recently has been identified. Together with Beclin1, Atg14L can bind to the kinases hVps34 and p150 to form a kinase complex. Three distinct Beclin1 complexes exist in the cell. The Atg14 complex (Beclin1, hVps34, hVps15, Atg14) promotes the autophagosome formation. The UVRAG complex (Beclin1, hVps34, hVps15, UVRAG) promotes autophagosome and endosome maturation. When Rubicon binds to a subpopulation of UVRAG proteins, the third complex (Beclin1, hVps34, hVps15, UVRAG, Rubicon) negatively regulates the process of autophagosome maturation and endosytosis.

Autophagy can be induced by serum deprivation. When such serum-starved cells are stained with an LC3 antibody and analyzed by flow cytometry, a decrease in fluorescence can be observed due to the degradation of LC3-II inside the autophagosomes.

Featured Product for flow Cytometry: Human LC3 Polyclonal Antibody (Product Code: PM036)
View the full product range here.

Tuesday, 11 October 2011

Leuko64: Routine diagnosis of inflammation and bacterial sepsis

Monitoring infection by the detection of CD64 on neutrophils - For use on multi-parameter flow cytometers.

Neutrophil CD64 expression is rapidly increased both in vitro and in vivo within hours by mediators of inflammation, such as interferon-gamma and G-CSF. The same change is observed in response to documented infection or tissue injury, indicating the measurement of neutrophil CD64 expression correlates with the presence of infection or sepsis in humans.

The Leuko64 assay is intended for use in routine diagnosis of inflammation and bacterial sepsis by the measurement of leukocyte and specifically neutrophil CD64 levels in blood.

Special Features of the Leuko64 assay:
1) CD64 is an early onset marker for inflammatory responses to infection or tissue injury,
2) Clear Distinction between inflammation and conditions like leukemia, pregnancy or steroid therapy.

Clinical Applications:
1) Screening for infection severity in outpatients and hospitalised patients
2) Therapeutic monitor of antibiotic response in infection
3) Monitoring post-operative and post-chemotherapy patients, HIV+ patients and others at risk of infection/sepsis.

Leuko64 (75 test) Product Code: LK64-75 Reduced price sample kits available, email office@caltagmedsystems.co.uk to receive your kit. Usual list price £392, limited time offer price £313.

Leuko64 (250 test) Product Code: LK64-250 £1035.

The Leuko64 Assay kit is CE marked as an IVD; FDA clearance and patents are pending.

Key Benefits:
1) Automated software, co-developed with Verity Software House, for flow cytometric and Cell-Dyn list mode data analysis. The QuantiCALC for Leuko64 software uses iterative cluster finding algorithms and is included in the assay kit.
2) Requires only 50 µl of blood and under one hour of hands-on time.
3) Superior diagnostic evaluation of infection - sensitivity 90.5%, specificity 96.3%, positive predictive value 95.0%, negative predictive value 92.9%
4) Standardized assay with internal calibrator and controls.
5) Automated user-friendly software allows for excellent reproducibility (CV < 5%).

Keep Us In Mind.....


...and save 10% on your orders.

Just quote our promotional code ‘Mind10’ on your next order to qualify.

This discount code is valid on all orders placed by the 31st December 2011, but it can’t be used in conjunction with any other offers.

We’re also offering extra discounts on large orders and there’s free shipping on orders over £1,000. Any questions? Just call our friendly team on 01280 827460 or email office@caltagmedsystems.co.uk to discuss your needs.

For details of exclusive offers/news/product information follow us on twitter @caltagmedsystem. Our Twitter account will let you know what is hot in the Life Science industry. Stay connected to the latest information about newly released products, new suppliers, exhibitions, and exciting promotions in real-time.

Follow us today to find out what this week’s twitter treat is.

Monday, 10 October 2011

Abnova – Polyethylene Glycol Matched Antibody Pair


This matched antibody pair set binds to the repeating subunits of the polyethylene glycol polymer and can be employed to detect and quantify PEGylated compounds.
Polyethylene Glycol (PEG) is a long chain polymer that has been approved by the Food and Drug Administration for human intravenous, oral and dermal applications. Covalent attachment of PEG (PEGylation) to proteins can reduce their immunogenicity, minimize proteolytic cleavage and increase their serum half-life. PEG has also been attached to small molecules and liposomes for more selective delivery. PEG-modification of superparamagnetic iron oxide and quantum dots can improve their biocompatibility and reduce non-specific uptake.

Characteristics of PEG

  • Water soluble, nontoxic, biocompatible
  • Covalently conjugated to proteins, small molecules, and particles
  • Decreased immunogenicity
  • Minimized proteolytic cleavage
  • Increased bioavailability
PEG Matched Antibody Pair
  • Capture antibody: mouse monoclonal anti-PEG, IgM
  • Detection antibody: mouse monoclonal anti-PEG, IgG1
Applications
  • Immunoblot
  • Immunoprecipitation
  • Sandwich ELISA
  • Flow Cytometry
Product Code: AP0001

Friday, 7 October 2011

BAFF – A Key Factor in Autoimmune Diseases


BAFF (B-cell activating factor; BLyS; B lymphocyte stimulator; TNFSF13B; TALL-1; CD257), belonging to the TNF family, is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune

For a quantitative and specific measurement of BAFF levels diseases, such as Sjogren’s syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukaemia (B-CCL).
  • The first “highly sensitive” mAb/mAb-based human BAFF immunoassay
  • Detects BAFF levels in in patients with healthy and pathological conditions
  • Secured re-supply – available from stock
  • Inter- and intra- batch reproducibility
  • Small original sample amounts – only 5ul needed
  • Works on serum, plasma and cell culture supernatant
BAFF ELISA Kit (Human) – Hypersensitive
Product Code: AG-45B-0001-KI01 (1 x 96 well plate)

Thursday, 6 October 2011

Upcoming Exhibitions...


Come and meet us at one of the following exhibition and vendor days that we are attending this year. we are exhibiting at a number of exhibitions in the remaining months on 2011, covering a vast range of topics and in many areas of the UK. Why not pop along to one and pay us a visit.


On 26th October 2011 we will be in Manchester at the Paterson Institute for Cancer Research.
Research spans the whole spectrum of cancer research, from programmes investigating molecular and cellular basis of cancer, to those focussed on translational research and development of therapeutics. We will be located in the coffee room so don’t be shy, come and see what treats we have.
For more information on this vendor day email: enquiries@picr.man.ac.uk

On 6th-8th November 2011 we will be in Liverpool exhibiting at the National Cancer Research Institute Cancer Conference.
This has become an annual event in the UK covering all aspects of cancer research. It aims to encourage the sharing of knowledge, ideas and best practice, and to promote cross-disciplinary collaboration.
For more information on this conference visit the website.

On 8th November 2011 we will be at Hixton Hall in Cambridge, exhibiting at the ELRIG Stem Cells and Regenerative Medicine conference.
This conference will highlight state of the art research and technology enabling the provision of stem cells, their differentiation into desired cell types as well as applications as potential therapeutic agents.
For more information on this conference visit the website or click here.

On 10th November 2011 we will be at UCL in London exhibiting at the Diabetes and Obesity Conference, hosted by the Association for the Study of Obesity (ASO).
The Association for the Study of Obesity (ASO) is the UK’s foremost charitable organisation dedicated to the understanding and treatment of obesity.
For more information on this event click here.

On 23rd November 2011 we will be in Cambridge visiting the Cambridge Institute for Medical Research (CIMR).
CIMR is a modern research facility in Cambridge UK, where clinical and basic science converge in the study of the molecular mechanisms of disease.
For more information on this event email: cimr-reception@lists.cam.ac.uk

On 15th December 2011 we will be in London at the Imperial College London Symposium: “Vascular Endothelium: Role in disease pathogenesis and as a therapeutic target”.
The event is co-organised by the Kennedy Institute of Rheumatology and the Cardiovascular Medicine Unit of Imperial College. It will bring together scientists and clinicians from basic and translational research, investigating the vascular endothelium in health, inflammation, cardiovascular disease and cancer.
For more information on this event click here.

Webmaster: AnnWebCom | Site design: custardcreative.co.ukCustard Creative Copyright 2005-2014 Caltag-Medsystems Limited - all rights reserved